Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of chronic heart failure~* Admission for acute decompensated heart failure~* There is no prespecified inclusion criterion with respect to heart failure etiology and/or ejection fraction~* Receipt of an oral loop diuretic for at least 1 month before hospitalization, at a dose between 80 mg and 240 mg daily in the case of furosemide and an equivalent dose in the case of a different loop diuretic (20 mg of torasemide or 1 mg of bumetanide was considered to be equivalent to 40 mg of furosemide)~Exclusion Criteria:~* Other etiologies of fluid overload different from heart failure~* Hyponatremia: any symptomatic sodium value or a sodium level below 125mmol/l~* Unstable patients: acute coronary syndrome, cardiogenic shock or ICU admission.~* Patients requiring inotropic agents or renal replacement therapies~* Life expectancy \< 6 months~* Prior treatment with thiazide-type diuretics~* Aldosterone antagonists are permitted if the patient had been taking them on a long-term basis (at least 30 days before randomisation)~* Pregnancy or breastfeeding period~* Active alcoholism and/or other substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Loop plus thiazide-type diuretic (Type: ACTIVE_COMPARATOR): Loop diuretic plus hydrochlorothiazide
- Loop diuretic plus placebo (Type: PLACEBO_COMPARATOR): Loop diuretic plus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).